PharmaEssentia announced on September 5 that it has submitted an application to Taiwan’s Food and Drug Administration (TFDA) to expand the indication of its novel drug Ropeginterferon alfa-2b (P1101) to include primary essential thrombocythemia (ET). The company also reported August revenue of NT$1.27 billion, marking the second-highest monthly revenue in its history—slightly down 2.14% from the previous month but up 41.35% year-over-year. U.S. shipments of Ropeg reached a new record high, while sales in Japan were slightly affected by national holidays.
Read more
